UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effect of Enzyme Inhibition on Perampanel Pharmacokinetics: Why Study Design Matters

Epilepsy research, 2017-08, Vol.134, p.41-48

2017

Volltextzugriff (PDF)

Eribulin shows high concentration and long retention in xenograft tumor tissues

Cancer chemotherapy and pharmacology, 2017-08, Vol.80 (2), p.377-384

2017

Volltextzugriff (PDF)

Characterization of the pharmacokinetics of a liposomal formulation of eribulin mesylate (E7389) in mice

International journal of pharmaceutics, 2013-02, Vol.443 (1-2), p.9-16

2013

Volltextzugriff (PDF)

Physiological, Pharmacokinetic, and Pharmacodynamic Changes in Space

Journal of clinical pharmacology, 2004-08, Vol.44 (8), p.837-853

2004

Volltextzugriff (PDF)

Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P-glycoprotein in CF-1 abcb1a-deficient mice and Caco-2 cells

Xenobiotica, 2011-04, Vol.41 (4), p.320-326

2011

Volltextzugriff (PDF)

Pharmacokinetic/ pharmacodynamic evaluation of anti-infective agents

Expert review of anti-infective therapy, 2005-06, Vol.3 (3), p.361-373

2005

Volltextzugriff (PDF)

A Transcellular Assay to Assess the P-gp Inhibition in Early Stage of Drug Development

Drug metabolism letters, 2013-07, Vol.6 (4), p.285-291

2013

Volltextzugriff (PDF)

Novel second generation analogs of eribulin. Part III: Blood–brain barrier permeability and in vivo activity in a brain tumor model

Bioorganic & medicinal chemistry letters, 2011-03, Vol.21 (6), p.1639-1643

2011

Volltextzugriff (PDF)

Pharmacokinetic characterization of a natural product–inspired novel MEK1 inhibitor E6201 in preclinical species

Cancer chemotherapy and pharmacology, 2012, Vol.69 (1), p.229-237

2012

Volltextzugriff (PDF)

New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial

The Lancet infectious diseases, 2021-08, Vol.21 (8), p.1129-1140

2021

Volltextzugriff (PDF)

Changes in perampanel levels during de‐induction: Simulations following carbamazepine discontinuation

Acta neurologica Scandinavica, 2020-08, Vol.142 (2), p.131-138

2020

Volltextzugriff (PDF)

Effect of Simulated Microgravity on the Disposition and Tissue Penetration of Ciprofloxacin in Healthy Volunteers

Journal of clinical pharmacology, 2005-07, Vol.45 (7), p.822-831

2005

Volltextzugriff (PDF)

Phase 1 Single Ascending and Multiple Ascending Dose Studies of Phosphodiesterase-9 Inhibitor E2027: Confirmation of Target Engagement and Selection of Phase 2 Dose in Dementia With Lewy Bodies Trial

Alzheimer disease and associated disorders, 2022-07, Vol.36 (3), p.200-207

2022

Volltextzugriff (PDF)

Simulation of changes in steady-state plasma concentrations of perampanel following discontinuation of the enzyme-inducing antiepileptic drug (EIAED) carbamazepine (P3.235)

Neurology, 2017-04, Vol.88 (16_supplement)

2017

Volltextzugriff (PDF)

Perampanel and Pregnancy (4272)

Neurology, 2020, Vol.94 (15_supplement)

2020

Volltextzugriff (PDF)

Predictions of the pharmacokinetic profile of perampanel during pregnancy using physiologically based pharmacokinetic (PBPK) modeling (P3.237)

Neurology, 2017-04, Vol.88 (16_supplement)

2017

Volltextzugriff (PDF)

Design, Synthesis, and Pharmacological Evaluation of Fluorinated Tetrahydrouridine Derivatives as Inhibitors of Cytidine Deaminase

Journal of medicinal chemistry, 2014-03, Vol.57 (6), p.2582-2588

2014

Volltextzugriff (PDF)

E2027, A NOVEL PHOSPHODIESTERASE-9 (PDE9) INHIBITOR IN DEVELOPMENT FOR TREATMENT OF DEMENTIA WITH LEWY BODIES (DLB), SHOWED NO CLINICALLY SIGNIFICANT DRUG INTERACTION WITH DILTIAZEM

Alzheimer's & dementia, 2018-07, Vol.14 (7), p.P289-P289

2018

Volltextzugriff (PDF)

P1‐055: E2027, A NOVEL PHOSPHODIESTERASE‐9 (PDE9) INHIBITOR IN DEVELOPMENT FOR TREATMENT OF DEMENTIA WITH LEWY BODIES (DLB), SHOWED NO CLINICALLY SIGNIFICANT DRUG INTERACTION WITH DILTIAZEM

Alzheimer's & dementia, 2018-07, Vol.14 (7S_Part_5), p.P289-P289

2018

Volltextzugriff (PDF)

POPULATION PHARMACOKINETIC/PHARMACODYNAMIC ANALYSES OF BAN2401 IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE: CORRELATION OF BAN2401 EXPOSURE, PET STANDARD UPTAKE VALUE RATIO, AND COGNITIVE OUTCOMES

Alzheimer's & dementia, 2019-07, Vol.15 (7), p.P1582-P1583

2019

Volltextzugriff (PDF)

P4‐657: POPULATION PHARMACOKINETIC/PHARMACODYNAMIC ANALYSES OF BAN2401 IN PATIENTS WITH EARLY ALZHEIMER'S DISEASE: CORRELATION OF BAN2401 EXPOSURE, PET STANDARD UPTAKE VALUE RATIO, AND COGNITIVE OUTCOMES

Alzheimer's & dementia, 2019-07, Vol.15, p.P1582-P1583

2019

Volltextzugriff (PDF)

P4‐657: POPULATION PHARMACOKINETIC/PHARMACODYNAMIC ANALYSES OF BAN2401 IN PATIENTS WITH EARLY ALZHEIMER'S DISEASE: CORRELATION OF BAN2401 EXPOSURE, PET STANDARD UPTAKE VALUE RATIO, AND COGNITIVE OUTCOMES

Alzheimer's & dementia, 2019-07, Vol.15 (7S_Part_30)

2019

Volltextzugriff (PDF)

Effect of Adjunctive Rufinamide in Pediatric Patients With Inadequately Controlled Lennox-Gastaut Syndrome (LGS): Interim Pharmacokinetic and Safety Results From Study 303 (P1.242)

Neurology, 2015-04, Vol.84 (14_supplement)

2015

Volltextzugriff (PDF)

Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective

Drug discovery today, 2017-10, Vol.22 (10), p.1447-1459

2017

Volltextzugriff (PDF)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel γ-secretase modulator, E2212, in healthy human subjects

Journal of clinical pharmacology, 2014-05, Vol.54 (5), p.528-536

2014

Volltextzugriff (PDF)

1 – 25 von 39

Suche als RSS-Feed

Aktive Filter

KollektionEZB*

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(25)

Publikationsform

Sprache

Englisch
(39)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(16)
Science & Technology
(16)
Humans
(12)
Pharmacology & Pharmacy
(11)
Animals
(9)
Male
(9)
Pharmacokinetics
(8)
Mice
(6)
Dose-Response Relationship, Drug
(5)
Female
(5)
Furans - Pharmacokinetics
(5)
Ketones - Pharmacokinetics
(5)
Antineoplastic Agents - Pharmacokinetics
(4)
Clinical Neurology
(4)
Mice, Inbred Balb C
(4)
Neurosciences & Neurology
(4)
P-Glycoprotein
(4)
Adult
(3)
Antineoplastic Agents
(3)
Area Under Curve
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effect of Enzyme Inhibition on Perampanel Pharmacokinetics: Why Study Design Matters

Eribulin shows high concentration and long retention in xenograft tumor tissues

Characterization of the pharmacokinetics of a liposomal formulation of eribulin mesylate (E7389) in mice

Physiological, Pharmacokinetic, and Pharmacodynamic Changes in Space

Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P-glycoprotein in CF-1 abcb1a-deficient mice and Caco-2 cells

Pharmacokinetic/ pharmacodynamic evaluation of anti-infective agents

A Transcellular Assay to Assess the P-gp Inhibition in Early Stage of Drug Development

Novel second generation analogs of eribulin. Part III: Blood–brain barrier permeability and in vivo activity in a brain tumor model

Pharmacokinetic characterization of a natural product–inspired novel MEK1 inhibitor E6201 in preclinical species

New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial

Changes in perampanel levels during de‐induction: Simulations following carbamazepine discontinuation

Effect of Simulated Microgravity on the Disposition and Tissue Penetration of Ciprofloxacin in Healthy Volunteers

Phase 1 Single Ascending and Multiple Ascending Dose Studies of Phosphodiesterase-9 Inhibitor E2027: Confirmation of Target Engagement and Selection of Phase 2 Dose in Dementia With Lewy Bodies Trial

Simulation of changes in steady-state plasma concentrations of perampanel following discontinuation of the enzyme-inducing antiepileptic drug (EIAED) carbamazepine (P3.235)

Perampanel and Pregnancy (4272)

Predictions of the pharmacokinetic profile of perampanel during pregnancy using physiologically based pharmacokinetic (PBPK) modeling (P3.237)

Design, Synthesis, and Pharmacological Evaluation of Fluorinated Tetrahydrouridine Derivatives as Inhibitors of Cytidine Deaminase

E2027, A NOVEL PHOSPHODIESTERASE-9 (PDE9) INHIBITOR IN DEVELOPMENT FOR TREATMENT OF DEMENTIA WITH LEWY BODIES (DLB), SHOWED NO CLINICALLY SIGNIFICANT DRUG INTERACTION WITH DILTIAZEM

P1‐055: E2027, A NOVEL PHOSPHODIESTERASE‐9 (PDE9) INHIBITOR IN DEVELOPMENT FOR TREATMENT OF DEMENTIA WITH LEWY BODIES (DLB), SHOWED NO CLINICALLY SIGNIFICANT DRUG INTERACTION WITH DILTIAZEM

POPULATION PHARMACOKINETIC/PHARMACODYNAMIC ANALYSES OF BAN2401 IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE: CORRELATION OF BAN2401 EXPOSURE, PET STANDARD UPTAKE VALUE RATIO, AND COGNITIVE OUTCOMES

P4‐657: POPULATION PHARMACOKINETIC/PHARMACODYNAMIC ANALYSES OF BAN2401 IN PATIENTS WITH EARLY ALZHEIMER'S DISEASE: CORRELATION OF BAN2401 EXPOSURE, PET STANDARD UPTAKE VALUE RATIO, AND COGNITIVE OUTCOMES

P4‐657: POPULATION PHARMACOKINETIC/PHARMACODYNAMIC ANALYSES OF BAN2401 IN PATIENTS WITH EARLY ALZHEIMER'S DISEASE: CORRELATION OF BAN2401 EXPOSURE, PET STANDARD UPTAKE VALUE RATIO, AND COGNITIVE OUTCOMES

Effect of Adjunctive Rufinamide in Pediatric Patients With Inadequately Controlled Lennox-Gastaut Syndrome (LGS): Interim Pharmacokinetic and Safety Results From Study 303 (P1.242)

Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel γ-secretase modulator, E2212, in healthy human subjects

Aktive Filter

Suchergebnisse filtern